
Contents
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Immunization Immunization
-
Immunity can be induced in 2 ways Immunity can be induced in 2 ways
-
Storage of vaccines Storage of vaccines
-
Administration of vaccines Administration of vaccines
-
Adult immunization Adult immunization
-
Influenza and pneumococcal vaccination Influenza and pneumococcal vaccination
-
Other necessary vaccinations Other necessary vaccinations
-
-
Contraindications to vaccination Contraindications to vaccination
-
Contraindications to live vaccines Contraindications to live vaccines
-
-
Vaccine damage payments Vaccine damage payments
-
-
Further information Further information
-
Patient information Patient information
-
Symptoms, signs, and notification of infectious disease Symptoms, signs, and notification of infectious disease
-
Lymphadenopathy Lymphadenopathy
-
Benign causes Benign causes
-
Malignant causes Malignant causes
-
Management in adults Management in adults
-
-
Fever in children under the age of 5 Fever in children under the age of 5
-
Rigors Rigors
-
Night sweats Night sweats
-
Pyrexia of unknown origin Pyrexia of unknown origin
-
Notifiable diseasesND Notifiable diseasesND
-
-
Illness in returning travellers Illness in returning travellers
-
History History
-
Examination Examination
-
Investigations Investigations
-
MalariaND MalariaND
-
Falciparum malaria Falciparum malaria
-
Benign malaria Benign malaria
-
-
TyphoidND and paratyphoidND TyphoidND and paratyphoidND
-
Dengue fever Dengue fever
-
Travellers’ diarrhoea Travellers’ diarrhoea
-
CholeraND CholeraND
-
Giardiasis Giardiasis
-
Amoebic dysenteryND Amoebic dysenteryND
-
-
Sexually transmitted infections Sexually transmitted infections
-
HIV HIV
-
TB TB
-
Hepatitis A Hepatitis A
-
Meningitis Meningitis
-
Hepatitis B & C Hepatitis B & C
-
-
Further information Further information
-
Infections in immunocompromised patients Infections in immunocompromised patients
-
Opportunistic infections Opportunistic infections
-
Organisms commonly involved Organisms commonly involved
-
Management Management
-
Prophylaxis Prophylaxis
-
Antibiotics Antibiotics
-
Active immunization Active immunization
-
Passive immunization Passive immunization
-
Immunoglobulin administration Immunoglobulin administration
-
-
Asplenic patients Asplenic patients
-
Ensure that asplenic patients have Ensure that asplenic patients have
-
-
HIV HIV
-
-
Further information Further information
-
Childhood viral infections Childhood viral infections
-
Management Management
-
Prevention of measles, mumps, and rubella Prevention of measles, mumps, and rubella
-
Prevention of chickenpox Prevention of chickenpox
-
Shingles Shingles
-
Complications Complications
-
-
-
Streptococcal and staphylococcal infections Streptococcal and staphylococcal infections
-
Streptococcal infection Streptococcal infection
-
Investigation Investigation
-
Treatment Treatment
-
-
Pneumococcal infection Pneumococcal infection
-
Presentations Presentations
-
Treatment Treatment
-
Childhood vaccination Childhood vaccination
-
Vaccination of high-risk groups Vaccination of high-risk groups
-
-
Scarlet fever Scarlet fever
-
Staphylococcal infection Staphylococcal infection
-
Presentation Presentation
-
Management Management
-
-
Staphylococcal scalded skin syndrome Staphylococcal scalded skin syndrome
-
Methicillin-resistant Staph. aureus (MRSA)N Methicillin-resistant Staph. aureus (MRSA)N
-
Toxic shock syndrome Toxic shock syndrome
-
-
Further information Further information
-
Other bacterial infections Other bacterial infections
-
Haemophilus influenzae Haemophilus influenzae
-
Haemophilus influenza type b (Hib) Haemophilus influenza type b (Hib)
-
Other types Other types
-
Management Management
-
-
Clostridium infections Clostridium infections
-
Tetanus (lockjaw)ND Tetanus (lockjaw)ND
-
Management Management
-
Prevention Prevention
-
-
DiphtheriaND DiphtheriaND
-
Presentation Presentation
-
Management Management
-
Prevention Prevention
-
-
Pseudomonas aeruginosa Pseudomonas aeruginosa
-
Enterobacteria Enterobacteria
-
-
Further information Further information
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Cite
Immunization
Immunity can be induced in 2 ways
Active immunity Induced using inactivated or attenuated live organisms or their products. Acts by inducing cell-mediated immunity and serum antibodies. Generally long-lasting
Passive immunity Results from injection of human immunoglobulin. The protection afforded is immediate but lasts only a few weeks
Storage of vaccines
Follow manufacturers’ instructions. Do not store vaccines in the door of a vaccine fridge and make sure there is a maximum and minimum thermometer in the fridge. Record readings regularly and discard vaccines if not stored at the correct temperature.
Administration of vaccines
Only suitably trained GPs/nurses should give immunizations. Check immunization is needed and the patient is fit. Check consent has been obtained and that immunizations are the correct ones and in date. Ensure resuscitation facilities are available. Record vaccine expiry date/batch number. Reconstitute vaccine (if necessary) and give according to manufacturer’s instructions. Record date and site in the medical notes.

In the UK, routine vaccinations for the under 5s are usually done in the GP surgery. Routine vaccinations for older children are normally done through the school health service. Schedule for childhood immunizations—see Table 18.1.
Disease (vaccine) . | Age . | Comment . |
---|---|---|
Tuberculosis (BCG) | High-risk neonates | 1 injection |
Diphtheria/tetanus/pertussis/ Haemophilus influenzae type b/inactivated polio (DTaP/IPV/Hib) | 2, 3, and 4mo | Primary course (3 doses, a month between each dose) |
Pneumococcal conjugate vaccine (PCV) | 2, 4, and 12–13mo | Primary course |
Rota virus vaccine (oral Rotarix®) | 2 and 3mo | Primary course |
Meningococcus type C conjugate vaccine (MenC) | 3 mo | 1st dose |
Meningococcus type C/ Haemophilus influenzae type b (Hib/MenC) | 12–13mo | Booster dose |
Measles/mumps/rubella (MMR) | 12–13mo | 1st dose |
Influenza (Fluenz® intranasal spray) | Annually age 2–16y | 1 dose per year |
Diphtheria/tetanus/acellular pertussis/inactivated polio (DTP/IPV) | 3y 4mo–5y (3y after completion of the 1° course) | Booster dose |
Measles/mumps/rubella (MMR) | 3y 4mo–5y | 2nd dose |
HPV vaccination | 12–13y (♀ only) | 3 doses over >6mo |
Tetanus/low-dose diphtheria (Td/IPV) /inactivated polio | 13–14y | Booster dose |
Meningococcus type C conjugate vaccine (MenC) | 13–14y (or before starting higher education if no booster at 13–14y) | Booster dose |
Disease (vaccine) . | Age . | Comment . |
---|---|---|
Tuberculosis (BCG) | High-risk neonates | 1 injection |
Diphtheria/tetanus/pertussis/ Haemophilus influenzae type b/inactivated polio (DTaP/IPV/Hib) | 2, 3, and 4mo | Primary course (3 doses, a month between each dose) |
Pneumococcal conjugate vaccine (PCV) | 2, 4, and 12–13mo | Primary course |
Rota virus vaccine (oral Rotarix®) | 2 and 3mo | Primary course |
Meningococcus type C conjugate vaccine (MenC) | 3 mo | 1st dose |
Meningococcus type C/ Haemophilus influenzae type b (Hib/MenC) | 12–13mo | Booster dose |
Measles/mumps/rubella (MMR) | 12–13mo | 1st dose |
Influenza (Fluenz® intranasal spray) | Annually age 2–16y | 1 dose per year |
Diphtheria/tetanus/acellular pertussis/inactivated polio (DTP/IPV) | 3y 4mo–5y (3y after completion of the 1° course) | Booster dose |
Measles/mumps/rubella (MMR) | 3y 4mo–5y | 2nd dose |
HPV vaccination | 12–13y (♀ only) | 3 doses over >6mo |
Tetanus/low-dose diphtheria (Td/IPV) /inactivated polio | 13–14y | Booster dose |
Meningococcus type C conjugate vaccine (MenC) | 13–14y (or before starting higher education if no booster at 13–14y) | Booster dose |
Hepatitis B vaccine is also offered to neonates born to hepatitis B +ve mothers <24h after birth with booster doses at 1mo, 2mo, and 1y—
p. 811
Adult immunization
Influenza and pneumococcal vaccination
Available as a Directed Enhanced Service—existing practices do not have preferred provider status. Additional payments are available through the Quality and Outcomes Framework for ensuring at-risk patients receive vaccination.
Other necessary vaccinations
Can be provided as an Additional Service. Opting out incurs a 2% ↓ in global sum. A list of eligible vaccinations and terms of eligibility is available on the BMA website ( www.bma.org.uk). Travel vaccinations that do not fall into these criteria can be administered as a private service.
Contraindications to vaccination
For specific contraindications to individual vaccinations consult the Green Book. General rules:
Acute illness Delay until fully recovered. Minor ailments without fever or systemic upset are not reasons to postpone immunization
Severe local reaction to previous dose Extensive area of redness/swelling that involves much of the antero-lateral surface of the thigh or a major part of the circumference of the upper arm
Severe generalized reaction to a previous dose Fever ≥39.5°C <48h after vaccination; anaphylaxis, bronchospasm, laryngeal oedema, and/or generalized collapse; prolonged unresponsiveness; prolonged high-pitched or inconsolable screaming for >4h; convulsions or encephalopathy <72h after vaccination
Contraindications to live vaccines
(BCG; shingles; measles; mumps; oral typhoid; rubella; yellow fever). Do not give live vaccines:
To pregnant women or immunocompromised patients—those on high-dose steroids for >1wk (>1mg/kg/d prednisolone for children or ≥40mg/d for adults); if haematological malignancy; if radiotherapy/chemotherapy within 6mo; or another immunodeficiency syndrome
<3wk after another live vaccine (but 2 live vaccines may be given together at different sites), or
With immunoglobulin (from 3wk before to 3mo after)
Patients with HIV who are not severely immunosuppressed may have live vaccine except BCG and yellow fever.
Vaccine damage payments
Only payable if a patient is >60% impaired by a vaccination given within the NHS. Recipients receive a lump sum. Further information: 01772 899944
www.gov.uk.
Further information
DH The Green book: immunisation against infectious disease. www.dh.gov.uk/greenbook
Patient information
NHS Choices www.nhs.uk/Conditions/vaccinations
Symptoms, signs, and notification of infectious disease
Specific symptoms and signs of infection depend on the infecting organism and organs affected. For example, a chest infection will cause respiratory symptoms; a urine infection, urinary tract symptoms. Symptoms suggesting an infectious cause include:
Lymphadenopathy
Palpable enlargement of the LNs.
Benign causes
Infective Bacterial—pyogenic, TB, brucella; fungal; viral—EBV, CMV, HIV; toxoplasmosis; syphilis
Non-infective Sarcoid, connective tissue disease (rheumatoid arthritis); skin disease (eczema, psoriasis); drugs (phenytoin); berylliosis
Malignant causes
Lymphoma, CLL, ALL, metastases.
Management in adults
Refer immediately for urgent investigationN if:
Rapidly growing
Non-tender, firm/hard lymph node, >3cm diameter
Lymph nodes associated with other unexplained signs of ill health (night sweats, weight loss, persistent fever)
Lymph nodes associated with other sinister signs, e.g. petechial rash (same day assessment), suspected head or neck tumour
Enlarged supraclavicular nodes in the absence of local infection
Most enlarged lymph nodes are reactive lymph nodes—suggested by a short history, soft tender mobile lump, and concurrent infection. If there are no sinister features, give these 2wk to settle. If not settling, check FBC, ESR ± EBV screen. Refer lymphadenopathy >1cm diameter persisting for >6wk for urgent further investigation.

Refer to paediatrics urgently, particularly if there is no evidence of local infection, if ≥1 of:
Non-tender, firm/hard LN
LN >2cm diameter
Progressively enlarging LNs
LNs associated with other signs of ill health (e.g. fever, weight loss)
Enlarged axillary nodes in the absence of local infection or dermatitis
Supraclavicular node involvement
Investigate with FBC and blood film if generalized lymphadenopathy
Oral temperature raised above 37.5°C. Normal range varies according to where measured—see Table 18.2. Common causes:
Place of measurement | Normal range |
Oral | 35.5–37.5°C (95.9–99.5°F) |
Rectal | 36.6–38.0°C (97.9–100.4°F) |
Axillary | 34.7–37.3°C (94.5–99.1°F) |
Ear | 35.8–38.0°C (96.4–100.4°F) |
Place of measurement | Normal range |
Oral | 35.5–37.5°C (95.9–99.5°F) |
Rectal | 36.6–38.0°C (97.9–100.4°F) |
Axillary | 34.7–37.3°C (94.5–99.1°F) |
Ear | 35.8–38.0°C (96.4–100.4°F) |
By far, the most common cause in general practice:
Viral infection (e.g. HIV, EBV, URTI, influenza)
UTI
Chest infection
Tonsillitis
OM
Sinusitis
Cholecystitis
Cellulitis
Do not forget tropical diseases, e.g. malaria in patients returning from abroad. Think of TB and SBE—especially in high-risk patients.
Lymphoma; leukaemia; solid tumours (e.g. hypernephroma).
Connective tissue disease and autoimmune disease (e.g. RA, SLE, PAN, polymyalgia rheumatica); sarcoidosis.
DVT; PE
e.g. antibiotics
Fever in children under the age of 5
p. 874
Rigors
Shaking episodes (sometimes violent) associated with sudden rise in fever.
Night sweats
Consider TB, lymphoma, leukaemia, solid tumour (e.g. renal carcinoma), menopause, anxiety states, drug causes, e.g. opioids, SSRIs.
Pyrexia of unknown origin
Defined as a fever (either intermittent or continuous) which has lasted for >3wk and for which no cause has been found. Recheck history. Re-examine carefully. Check FBC; EBV screen (depending on age of the patient); ESR; CRP; LFTs; amylase, urine (M,C&S); viral titres (including HIV); blood cultures; and CXR. If cause does not become obvious refer urgently for further investigation.
Notifiable diseasesND
Notification of certain diseases is required under the Public Health (Control of Disease) Act 1984 and Health Protection (Notification) Regulations 2010. Notification is made to the ‘proper officer of the local authority’ on forms available from the HPA website ( www.hpa.org.uk). Diseases included:
Acute encephalitis
Acute infectious hepatitis
Acute meningitis
Acute poliomyelitis
Anthrax
Botulism
Brucellosis
Cholera
Diphtheria
Enteric fever (typhoid /paratyphoid)
Food poisoning
Haemolytic uraemic syndrome
Infectious bloody diarrhoea
Invasive group A streptococcal disease and scarlet fever
Legionnaire’s disease
Leprosy
Malaria
Measles
Meningococcal septicaemia
Mumps
Plague
Rabies
Rubella
SARS
Smallpox
Tetanus
Tuberculosis
Typhus
Viral haemorrhagic
fever
Whooping cough
Yellow fever
In addition, notify other infections or contamination which could present significant risk to human health.
Illness in returning travellers
In all returned travellers who present unwell, consider imported disease in addition to the usual differential diagnosis. Tropical medicine is a specialized field. If unsure, seek expert advice by telephone or admit the patient.
History
Ask about:
Symptoms
Malaria prophylaxis
Areas travelled to (including brief stopovers)
Health of members of the travel party
Duration of travel
Sexual contacts whilst abroad
Immunizations prior to travel
Medical treatment abroad
Examination
Full examination. Particularly check for fever, jaundice, abdominal tenderness, chest signs, rashes, lymphadenopathy.
Investigations
Depend on symptoms and examination findings. Consider: FBC, malaria testing (consult local protocols), LFTs, viral serology, blood culture, stool culture (ensure it is fresh), MSU.
MalariaND
2,000 cases/y are notified in the UK. Easy to miss.
Symptoms Malaria is a great mimic and can present with virtually any symptoms. Usually consists of a prodrome of headache, malaise, myalgia, and anorexia followed by recurring high fevers, rigors, and drenching sweats lasting 8–12h at a time
Examination May be normal—look for anaemia, jaundice ± hepatosplenomegaly
Investigation In all cases of fever in patients who have returned from a malarial endemic area—even if the plane just landed in a malarial area en route. Send a blood test for malaria daily for 3d. Tests include thick and thin film, dipstick or nucleic acid testing depending on local arrangements.
Management Admit for further investigation and treatment if:
Very unwell
Unable to check a malaria test (e.g. presentation at a weekend or out of hours)
Malaria test +ve
Persistent fever despite −ve malaria test
Falciparum malaria
Caused by Plasmodium falciparum. Accounts for ~½ UK cases—it may not present for up to 3mo after return from a malarial area. Can be fatal in <24h—especially if it occurs in pregnant women or small children (<3y). Complications: cerebral malaria (80% deaths); hypoglycaemia; renal failure; pulmonary oedema; splenic rupture; disseminated intravascular coagulation; death.
Benign malaria
Caused by P. vivax, P. ovale, and P. malariae. May cause illness up to 18mo after return. All have very low mortality. Relapse may occur at intervals after initial infection as parasites lie dormant in the liver (P. vivax and P. ovale) or blood (P. malariae).
TyphoidND and paratyphoidND
Caused by Salmonella typhi and Salmonella paratyphi; ∼200 cases/y are notified in the UK.
Spread By the faecal–oral route.
Incubation 3d–3wk
Symptoms Usually malaise, fever, headache, cough, constipation (or diarrhoea), nosebleeds, bruising, and/or abdominal pain
Examination Pyrexia; relative bradycardia; rose-coloured spots on the trunk (40%); splenomegaly; CNS signs (coma, delirium, meningism)
Management Admit for further investigation and antibiotics
Prognosis 10% die if untreated—<0.1% if treated; 1% become chronic carriers after infection
Dengue fever
Viral infection endemic in tropical and subtropical regions. ∼150 cases/y are notified in the UK.
Spread By the day-biting Aedes mosquito
Incubation 4–7d
Symptoms/examination Usually presents with a flu-like illness, sudden high fever ± red, maculopapular rash (appears 2–5d after the fever). Other symptoms—fatigue, headache, arthralgia, myalgia, nausea and vomiting, lymphadenopathy, skin hypersensitivity
Dengue haemorrhagic fever Rare, severe form of dengue fever with poor prognosis. Purpuric rash appears 2–3d after onset of symptoms; minor injuries may cause bleeding; shock → death. Risk factors—previous dengue infection, age <12y, ♀, Caucasian
Management Admit; treatment is supportive
Travellers’ diarrhoea
CholeraND
Caused by Gram −ve bacterium Vibrio cholerae.
Spread By faecal–oral route
Incubation Few hours–5d
Presentation Profuse watery stool, fever, vomiting, dehydration
Management Admit. Treatment is with rehydration ± antibiotics
Giardiasis
∼3,800 cases/y are notified in the UK. Flagellate protozoan. Infection is suggested by an incubation period ≥2wk; watery stool with flatus ++ (explosive diarrhoea); no fever. Stool microscopy may be −ve. If suspected treat with metronidazole. Rapid response is diagnostic.
Amoebic dysenteryND
∼100 cases/y are notified in the UK. May begin years after infection. Diarrhoea begins slowly becoming profuse and bloody ± fever ± malaise. Diagnosis is confirmed by microscopy of fresh stool. Take specialist advice on management.
Sexually transmitted infections
HIV
p. 746
TB
p. 326
Hepatitis A
p. 422
Meningitis
p. 1078
Hepatitis B & C
p. 742
Further information
Health Protection Agency (HPA) Topics A–Z: malaria, giardia, cholera. www.hpa.org.uk
Infections in immunocompromised patients
Infections in patients whose host defence mechanisms are compromised range from minor to fatal. They are often caused by organisms that normally reside on body surfaces.
Opportunistic infections
Infections from endogenous microflora that are non-pathogenic or from ordinarily harmless organisms. Occur if host defence mechanisms have been altered by:
Age
Infection
Burns
Neoplasms
Metabolic disorders
Irradiation
Foreign bodies
Corticosteroids
Immunosuppressive or cytotoxic drugs
Diagnostic or therapeutic instrumentation
The precise character of the host’s altered defenses determines which organisms are likely to be involved. These organisms are often resistant to multiple antibiotics.
Organisms commonly involved
E. coli
CMV
Pneumocystis
Candida
Herpes viruses
Toxoplasmosis
Mycobacteria
Non-pathogenic streptococci
Cryptococcal infection
Management
Expert care is always required—refer promptly to the consultant responsible for the patient.
Prophylaxis
Antibiotics
Used for prevention of:
TB and meningitis in exposed patients
Recurrent UTIs
Streptococcal infection in asplenic/hyposplenic patients
Bacterial infections in granulocytopenic patients
Pneumocystis in AIDS patients
Watch for signs of superinfection with resistant organisms.
Active immunization
See Table 18.3.
Age at presentation . | Vaccination schedule . |
---|---|
<2y | • Routine childhood vaccination schedule ( • Further booster dose of MenACWY >1mo after the 12–13mo routine Hib/MenC and PCV13 vaccination • One further dose of Hib/MenC and PPV at >2y of age |
2–5y | • If already vaccinated with PCV7, vaccinate with PCV13, (2 doses > 2 months apart) and then, after ≥2mo, with PPV • If already vaccinated with PCV13, vaccinate immediately with PPV • Vaccinate immediately with Hib/MenC booster • 1mo after Hib/MenC booster, vaccinate with MenACWY |
>5y | • Give Hib/MenC and PPV immediately • 1mo after Hib/MenC and PPV, vaccinate with MenACWY |
Age at presentation . | Vaccination schedule . |
---|---|
<2y | • Routine childhood vaccination schedule ( • Further booster dose of MenACWY >1mo after the 12–13mo routine Hib/MenC and PCV13 vaccination • One further dose of Hib/MenC and PPV at >2y of age |
2–5y | • If already vaccinated with PCV7, vaccinate with PCV13, (2 doses > 2 months apart) and then, after ≥2mo, with PPV • If already vaccinated with PCV13, vaccinate immediately with PPV • Vaccinate immediately with Hib/MenC booster • 1mo after Hib/MenC booster, vaccinate with MenACWY |
>5y | • Give Hib/MenC and PPV immediately • 1mo after Hib/MenC and PPV, vaccinate with MenACWY |
PCV7—pneumococcal conjugate 7-valent vaccine.
PCV13—pneumococcal conjugate 13-valent vaccine.
PPV—pneumococcal polysaccharide vaccine.
Hib/MenC—Haemophilus influenza b/meningitis conjugate vaccine.
MenACWY—meningitis quadrivalent (ACWY) conjugate vaccine.
Passive immunization
Can prevent or ameliorate herpes zoster (VZ-Ig), hepatitis A and B, measles, and cytomegalovirus infection in selected immunosuppressed patients. If a patient is in contact with any of these diseases seek advice from the consultant looking after the patient or a consultant in communicable disease control.
Immunoglobulin administration
Effective for patients with hypogammaglobulinaemia. Given on a regular basis by IV infusion.
Asplenic patients
All asplenic patients (or functionally asplenic patients, e.g. patients with sickle cell disease) are at ↑ risk of bacterial infection. Warn patients about severe malaria and other tropical infections when travelling abroad. Admit to hospital if infection develops despite prophylactic measures.
Ensure that asplenic patients have
Vaccinations See Table 18.3
Prophylactic antibiotics Oral penicillin continuously until age 16y or for 2y post-splenectomy—whichever is longer
Standby amoxicillin To start if symptoms of infection begin
Patient-held card Alerting health professionals to infection risk—cards and information leaflets for patients are available from www.orderline.dh.gov.uk
0300 123 1002
HIV
p. 746
Start vaccinations ≥2wk before splenectomy or starting immuno-suppressive treatment.
Further information
DH The Green Book: immunization against infectious disease. www.dh.gov.uk/greenbook
Childhood viral infections
Management
For infections listed in Table 18.4, management is supportive with paracetamol, fluids ± antibiotics for 2° infection. Teething gels may soothe mouth lesions in hand, foot, and mouth disease. Admit if any serious complications develop.
Condition . | Duration . | Main symptoms . |
---|---|---|
Measles ND | 10d | Incubation 10–14d Early symptoms Fever, conjunctivitis, cough, coryza, LNs Later symptoms Koplik’s spots (tiny white spots on bright red background found on buccal mucosa of cheeks), rash (florid maculopapular appears after 4d—becomes confluent) Complications Bronchopneumonia, otitis media, stomatitis, corneal ulcers, gastroenteritis, appendicitis, encephalitis (1:1,000 affected children), subacute sclerosing panencephalitis (rare) |
Rubella ND (German measles) | 10d | Incubation 14–21d Symptoms Mild and may pass unrecognized. Fever, LNs (including suboccipital nodes), pink maculopapular rash which lasts 3d Complications Birth defects if infected in pregnancy; arthritis (adolescents); thrombocytopenia (rare); encephalitis (rare) |
Mumps ND | 10d | Incubation 16–21d Symptoms Subclinical infection is common. Fever, malaise, tender enlargement of one or both parotids ± submandibular glands Complications Aseptic meningitis; epididymo-orchitis; pancreatitis |
Chickenpox | 14d | Incubation 10–21d (infectious 1–2d before rash appears and for 5d afterwards) Symptoms Rash ± fever. Spots appear in crops for 5–7d on skin and mucus membranes and progress from macule → papule → vesicle then dry and scab over |
Roseola infantum | 4–7d | Child <2y Symptoms High fever, sore throat and lymphadenopathy, macular rash appears after 3–4d when fever ↓ |
Erythema infectiosum (Fifth disease/ slapped cheek) | 4–7d | Parvovirus infection Symptoms Erythematous maculopapular rash starting on the face (‘slapped cheeks’), reticular, ‘lacy’ rash on trunk and limbs, mild fever, arthralgia (rare) Contact with parvovirus in pregnancy— |
Hand, foot, and mouth disease | 5–7d | Coxsackie virus infection Symptoms Oral blisters/ulcers, red-edged vesicles on hands and feet, mild fever |
Condition . | Duration . | Main symptoms . |
---|---|---|
Measles ND | 10d | Incubation 10–14d Early symptoms Fever, conjunctivitis, cough, coryza, LNs Later symptoms Koplik’s spots (tiny white spots on bright red background found on buccal mucosa of cheeks), rash (florid maculopapular appears after 4d—becomes confluent) Complications Bronchopneumonia, otitis media, stomatitis, corneal ulcers, gastroenteritis, appendicitis, encephalitis (1:1,000 affected children), subacute sclerosing panencephalitis (rare) |
Rubella ND (German measles) | 10d | Incubation 14–21d Symptoms Mild and may pass unrecognized. Fever, LNs (including suboccipital nodes), pink maculopapular rash which lasts 3d Complications Birth defects if infected in pregnancy; arthritis (adolescents); thrombocytopenia (rare); encephalitis (rare) |
Mumps ND | 10d | Incubation 16–21d Symptoms Subclinical infection is common. Fever, malaise, tender enlargement of one or both parotids ± submandibular glands Complications Aseptic meningitis; epididymo-orchitis; pancreatitis |
Chickenpox | 14d | Incubation 10–21d (infectious 1–2d before rash appears and for 5d afterwards) Symptoms Rash ± fever. Spots appear in crops for 5–7d on skin and mucus membranes and progress from macule → papule → vesicle then dry and scab over |
Roseola infantum | 4–7d | Child <2y Symptoms High fever, sore throat and lymphadenopathy, macular rash appears after 3–4d when fever ↓ |
Erythema infectiosum (Fifth disease/ slapped cheek) | 4–7d | Parvovirus infection Symptoms Erythematous maculopapular rash starting on the face (‘slapped cheeks’), reticular, ‘lacy’ rash on trunk and limbs, mild fever, arthralgia (rare) Contact with parvovirus in pregnancy— |
Hand, foot, and mouth disease | 5–7d | Coxsackie virus infection Symptoms Oral blisters/ulcers, red-edged vesicles on hands and feet, mild fever |
Prevention of measles, mumps, and rubella
Measles, mumps, and rubella (MMR) vaccination consists of live attenuated measles, mumps, and rubella viruses. Vaccine viruses are not transmitted.
Offer MMR to all children after their first birthday and again pre-school. Re-immunization is needed if given to children of <1y. Children with chronic illness, e.g. CF, are at particular risk from measles and should be immunized. Malaise, fever, and rash are common ~1wk after immunizations and last 2–3d. Advise on fever management. There is no link between MMR and autism or inflammatory bowel disease
Offer children aged >18mo who have not been vaccinated (or whose vaccination status is unclear) 2 doses of MMR vaccine ≥1mo apart; if the child has received 1 dose of MMR, give a booster dose
Offer MMR to women of childbearing age who are not immune to rubella (i.e. have not had 2 doses of MMR or are seronegative)
There is no evidence that vaccination in pregnancy is harmful, but do not give to women known to be pregnant and advise women who are vaccinated to avoid pregnancy for 1mo afterwards.
Prevention of chickenpox
Offer chickenpox (varicella) immunization (2 doses 4–8wk apart) to non-immune healthcare workers who have direct patient contact and susceptible close contacts of immunocompromised patients where continuing contact is unavoidable. Consider those with a definite history of varicella infection, immune—antibody-test others. Vaccination is contraindicated if pregnant or immunocompromised
Non-immune immunosuppressed patients, pregnant women, or neonates ( p. 808) with significant exposure to chickenpox/shingles should receive zoster immunoglobulin (VZ-Ig) <3d after contact. Check antibody levels if immune status is unknown
Shingles
Reactivation of latent chickenpox virus. Shingles cannot be acquired by exposure to chickenpox but contacts of patients with shingles can develop chickenpox. Infectious until all lesions have scabbed.
Incidence 1 in 25. Any age—more common if immunocompromised
Presentation Unilateral pain precedes a vesicular rash by 2–3 d. Crops of vesicles appear over 3–5d and are in the distribution of ≥1 adjacent dermatomes. The affected area is usually hyperaesthetic—pain may be severe. Lesions scab over and fall off in <14d
Management Treat as for chickenpox. Oral antivirals (e.g. aciclovir 800mg 5x/d) are only effective if initiated <48h after onset of the rash. If immunocompromised admit for IV antivirals
Prevention There is a routine shingles vaccination programme for adults aged 70y (and 79y if not previously vaccinated) in the UK
Complications
Post-herpetic neuralgia; dissemination to other areas (immunosuppressed patients—admit for IV antivirals); eye involvement—refer for same day assessment to ophthalmology; Ramsay Hunt syndrome ( p. 538).
Streptococcal and staphylococcal infections
Streptococcal infection
Several groups are pathogenic to man—A, B, C, G, D, and viridans streptococci. Presentation is varied:
Pharyngitis
Tonsillitis
Wound/skin infections
Septicaemia
Scarlet fever
Pneumonia
Rheumatic fever
Glomerulonephritis
Neonatal sepsis
Postpartum sepsis
Endocarditis
Septic arthritis
Pneumonia
UTI
Dental caries
Investigation
Diagnosis is usually clinical. Evidence of infection can be gained by measuring changing antibody response (ASO titres). ASO titres are ↑ in ~80% infections. Swabs are +ve if infection is on the skin or in the throat or vagina.
Treatment
Most streptococci are sensitive to penicillin (e.g. penicillin V 250–500mg qds for 7–10d) although resistance is increasingly common.
Pneumococcal infection
There are >85 types of S. pneumoniae. Pneumococci are carried in the noses and throats of half the population. In most people they are harmless. Spread is by droplet infection.
Presentations
Pneumonia
Acute otitis media
Sinusitis
Meningitis
Endocarditis
Septic arthritis (rare)
Peritonitis (rare)
Treatment
Amoxicillin 250–500mg tds for 7d (clarithromycin in allergic individuals). Resistance to penicillin in the community is still low.
Childhood vaccination
Routine vaccination is offered as part of the childhood immunization programme ( p. 645) using 13-valent pneumococcal conjugate vaccine (PCV) given at 2mo, 4mo, and 12–13mo of age.
Vaccination of high-risk groups
A single dose of pneumococcal polysaccharide vaccine (PPV) is indicated for high-risk patients (see Box 18.1) who have not previously been vaccinated. Special rules apply to patients who are immunosuppressed or have deficient spleens (see Table 18.4, p. 651). Booster doses are not needed except for patients with asplenia or nephrotic syndrome—when give a booster after 5–10y.
Those:
≥65y of age
With coeliac disease
With a cochlear implant
With asplenia/functional asplenia, e.g. splenectomy, sickle cell
With immune deficiency due to disease (e.g. lymphoma, Hodgkin’s disease, multiple myeloma, HIV) or treatment (e.g. chemotherapy, prolonged systemic steroids)
With chronic heart disease, lung disease (e.g. asthma, COPD), renal disease (or nephritic syndrome), or liver disease
With DM requiring insulin or oral hypoglycaemic drugs, and/or
With CSF shunt/other conditions where leakage of CSF fluid can occur
Scarlet fever
Group A haemolytic streptococcal infection. Incubation: 2–4d. Presents with fever, malaise, headache, tonsillitis, rash (fine punctate erythema sparing face, ‘scarlet’ facial flushing), and strawberry tongue (initially white turning red by third/fourth day). Treat with penicillin V 250–500mg qds for 10d (or clarithromycin if allergic). Complications include rheumatic fever ( p. 276) and acute glomerulonephritis.
Staphylococcal infection
Usually Staph. aureus—occasionally Staph. epidermidis. Carried in the nose of ∼30% of healthy adults. Antibiotic-resistant strains are common.
Presentation
Breast abscess/mastitis
Abscesses/furuncles/carbuncles
Septicaemia
Endocarditis
Wound infection
Osteomyelitis/septic arthritis
Pneumonia—especially patients with COPD, influenza, or those receiving corticosteroids or immunosuppressive therapy
Neonatal infections—usually appear <6wk after birth—pustular or bullous skin lesions on neck, axilla, or groin
Management
Antibiotics (usually flucloxacillin 250–500mg qds or clarithromycin 250–500mg bd for 7–10d), abscess drainage where appropriate and general supportive measures. Where possible obtain specimens for culture before instituting or altering antibiotic regimens.
Staphylococcal scalded skin syndrome
p. 903
Methicillin-resistant Staph. aureus (MRSA)N
MRSA acts in the same way as any other Staph. aureus—it is carried harmlessly in most but occasionally causes a range of infections. It is only different because of its multiple resistance to antibiotics. Often contracted in hospital.
↓ tendency for multiple resistance by prudent use of antibiotics
Wash hands thoroughly with an appropriate antibacterial preparation if they appear soiled
If hands appear clean, wash with an alcoholic rub between each and every patient contact
Follow local policies for management of patients who are known to be infected with or carry MRSA
Toxic shock syndrome
Caused by staphylococcal exotoxin.
Risk factors Tampon use; postpartum; staphylococcal wound infection; influenza; osteomyelitis; cellulitis
Presentation Sudden onset of high fever, vomiting, diarrhoea, confusion, and skin rash. May progress to shock ± death
Management Admit as a medical emergency—mortality 8–15%
Further information
National Electronic Library for Infection Antimicrobial resistance website www.antibioticresistance.org.uk
Health Protection Agency (HPA) Topics A–Z: streptococcal infections, Staphylococcus aureus www.hpa.org.uk
Nathwani D, Morgan M, Masterton RG, et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community.

Other bacterial infections
Haemophilus influenzae
Haemophilus influenza type b (Hib)
Vaccination against Hib is routinely offered to all children ( p. 645) and immunocompromised patients (
p. 651). Prior to routine vaccination, Hib infection accounted for 60% of meningitis in children aged <5y. It was also a common cause of epiglottitis, septicaemia, and septic arthritis/osteomyelitis. Infection is now rare.
Other types
Non-encapsulated Haemophilus influenzae (ncHi) usually causes non-invasive respiratory tract infections, e.g. OM, sinusitis. It can cause invasive disease in neonates (<1mo of age) and those with co-morbidities e.g. malignancy, immunosuppression, DM, chronic renal/liver/lung disease. Other H. influenzae serotypes (Hia, Hic, Hid, Hie, Hif) only rarely cause invasive disease.
Management
Organisms are often penicillin-resistant. Use an alternative antibiotic e.g. clarithromycin or doxycycline. If severe infection, admit.
Clostridium infections
Anaerobic, spore-forming bacilli found in dust, soil, vegetation, and GI tracts of humans and animals. 25–30 species cause disease in humans. Presentations:
Food poisoning—C. perfringens
Pseudomembranous colitis—overgrowth of C. difficile following antibiotic therapy—presents with bloody diarrhoea. Treated with vancomycin or metronidazole if toxin is isolated from stool
Botulism—caused by a toxin released by C. botulinum which is ingested in contaminated food—presents with neurological symptoms and warrants immediate admission for antitoxin
Wound infections—C. perfringens causes cellulitis which may → gas gangrene, septicaemia ± death—admit for IV antibiotics
Tetanus
Tetanus (lockjaw)ND
∼6 cases and 1 death every year in the UK. Incubation: 2–50d. C. tetani infects contaminated wounds that may be trivial, the uterus postpartum (maternal tetanus), or newborn umbilicus (tetanus neonatorum). Tetanus toxin → generalized or localized tonic spasticity ± tonic convulsions. Suspect in any patient who has not been immunized who develops muscle stiffness/spasm several days after suffering a skin wound or burn.
Management
If suspected admit for specialist care. Treatment is with antitoxin, wound debridement, and general support. Effects may last several weeks. Mortality—40%.

Any burn/wound sustained >6h before surgical treatment of that wound or any burn or wound that:
Has a significant amount of dead tissue within it
Is a puncture-type wound
Has had contact with soil/manure likely to harbour tetanus organisms
Is clinically infected
Prevention
Tetanus vaccine:
Primary immunization 3 doses of vaccine each 1mo apart. If the schedule is disrupted the course should be resumed from where it was stopped as soon as possible
Booster doses in children One dose >3y after the 1° course of immunization (pre-school) and another 10y later
Booster doses in adults 10y after the primary course and again 10y later. Probably gives life-long protection. If an adult has received >5 doses in total further routine boosters are not recommended
Open wounds p. 1107
DiphtheriaND
Caused by Corynebacterium diphtheriae. Rare in the UK since routine immunization. Spread by droplet infection or contact with articles soiled by an infected person. Incubation: 2–5d.
Presentation
In countries where hygiene is poor cutaneous diphtheria is the predominant form. Elsewhere, characterized by an inflammatory exudate which forms a greyish membrane in the respiratory tract (may cause respiratory obstruction). C. diphtheriae secretes a toxin which affects myocardium, nervous and adrenal tissues.
Management
Admit for antitoxin and IV antibiotics. Patients may be infectious for up to 4wk but carriers shed C. diphtheriae for longer.
Prevention
Vaccination—given routinely in childhood in the UK ( p. 645). In addition give booster dose to people in contact with a patient with diphtheria or carrier, or before travel to epidemic or endemic areas.
Pseudomonas aeruginosa
Common. Treatment is difficult due to multiple antibiotic resistance—if suspected, send specimen for M,C&S.
In immunocompetent patients may cause UTI, wound infections (particularly leg ulcers—gives a characteristic greenish colouring), osteomyelitis, and skin infections (e.g. otitis externa)
In immunocompromised patients and patients with CF, it is a common cause of pneumonia and septicaemia
Enterobacteria
Examples include:
Salmonella
Shigella
Escherichia
Klebsiella
Enterobacter
Proteus
Morganella
Providencia
Yersinia
Some are normal gut commensals. Others are pathogenic causing:
Diarrhoea and intra-abdominal infections e.g. peritonitis, hepatobiliary
UTI—often E. coli; Proteus species are associated with bladder stones
Septicaemia and/or meningitis—E. coli is the most common cause of meningitis in neonates
Chest infection—Klebsiella may cause a severe form of pneumonia
Endocarditis—rare
Organisms are usually sensitive to trimethoprim. Severe infection requires admission to hospital for IV antibiotics.
Further information
Health Protection Agency (HPA) Topics A–Z: Haemophilus influenza, Pseudomonas, Clostridium, tetanus, diphtheria www.hpa.org.uk
Month: | Total Views: |
---|---|
November 2022 | 1 |
December 2022 | 2 |
March 2023 | 1 |
May 2023 | 1 |
June 2023 | 3 |
October 2023 | 3 |
January 2024 | 2 |
February 2024 | 1 |
March 2024 | 1 |
June 2024 | 1 |